Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Emerging (Phase 3 ongoing) | Strong (FDA-approved) |
Triple incretin agonist (GIP/GLP-1/glucagon receptor). Combines appetite suppression and insulin sensitization of GLP-1 with the thermogenic and lipolytic effects of glucagon receptor activation. Produced the greatest weight loss of any anti-obesity agent in Phase 2 trials (~24% at 48 weeks).
Dual GIP/GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, slows gastric emptying, and acts on hypothalamic appetite centers. Produces greater weight loss than semaglutide in head-to-head trials. Also improves cardiovascular risk markers.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →